A retrospective evaluation of 200 consecutive recipients of autologous peripheral blood stem cell transplantation (PBSCT) was conducted to ascertain the incidence and outcome of infection with Clostridium difficile. The diagnosis was confirmed in 14 patients with diarrhea (15 episodes) at a median of 33 days after stem cell infusion. Five patients were neutropenic at the time of diagnosis. Every individual had adverse known risk factors such as recent or current use of antibiotic, corticosteroid and antiviral therapy, recent administration of myeloablative chemotherapy and numerous, prolonged periods of hospitalization. Diarrhea, frequently hemorrhagic, was the most common presenting feature along with fever, abdominal cramps and abdominal distention. Diagnosis was established by the stool-cytotoxin test. Response to standard treatment with oral vancomycin or metronidazole was prompt despite the presence of several adverse prognostic features in these patients. There was only one instance of relapse which was also treated successfully. Several transplant-related variables such as age, sex, underlying malignancy, myelo-ablative regimen, duration of neutropenia, and prophylactic use of oral ampicillin underwent statistical analysis but failed to be predictive of C. difficile infection in such a setting. Finally, C. difficile is not uncommon after autologous PBSCT and must be included in the differential diagnosis in any such patient with diarrhea.
microbial agents such as clindamycin, sulfonamides, tetracyclines, penicillins and cephalosporins can all disrupt the normal colonic flora and lead to an intestinal environment that is conducive to the overgrowth of C. difficile. [3] [4] [5] Furthermore, a suitable external environment is provided by hospitals and nursing facilities which act as an exogenous source of C. difficile organisms and spores. 1, [6] [7] [8] [9] [10] [11] [12] [13] However, not every case of C. difficile infection is preceded by antibiotic therapy. Other risk factors include recent cancer chemotherapy 14 and anti-viral chemotherapy. 15 Patients undergoing bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT) appear to be a group at particularly high risk because they are treated with numerous antibiotics, are hospitalized for prolonged periods of time, receive myelo-ablative chemotherapy causing severe pancytopenia, and are severely immunocompromised for several months to years. Surprisingly, there are few prior reports of C. difficile infection occurring in this setting. 16, 17 We evaluated 200 individuals with a variety of malignancies who received high-dose chemotherapy followed by autologous PBSCT. The incidence, clinical features, treatment and outcome of C. difficile infection in these patients is described.
Materials and methods
Two hundred consecutive patients who underwent autologous PBSCT between March 1993 and August 1996, at the University of Connecticut Health Center, Farmington, CT, USA, were eligible for this retrospective evaluation. Clinical data were obtained from comprehensive chart reviews in all patients ( Table 1) .
The underlying malignancies included carcinoma of the breast (n = 99), non-Hodgkin's lymphoma or Hodgkin's disease (n = 65), multiple myeloma (n = 14), ovarian cancer (n = 7), acute leukemia (n = 6) and miscellaneous solid tumors (n = 9). During the 30 days preceding the initiation of myeloablative conditioning chemotherapy, all 200 patients received a stem cell mobilizing chemotherapy regimen as follows: etoposide 60 mg/kg intravenously (n = 40); cyclophosphamide 3 g/m 2 intravenously (n = 3); etoposide 60 mg/kg intravenously and cyclophosphamide 3 g/m 2 intravenously (n = 17); and etoposide 60 mg/kg intravenously, cyclophosphamide 3 g/m 2 intravenously, and paclitaxel 200 mg/m 2 intravenously (n = 140). Every patient received prophylactic ciprofloxacin 500 mg orally twice daily from the completion of chemotherapy until 2 intravenously (BUCAT) (n = 126). Five patients received other regimens. Previously collected and cryopreserved autologous peripheral blood stem cells were infused on day zero. All patients were hospitalized for 4-6 weeks in isolation in a hepa-filtered, positive-pressure setting in the bone marrow transplant unit. Every individual older than 12 years of age received prophylactic ciprofloxacin 500 mg orally twice daily from the beginning of myelo-ablative chemotherapy (day −8 to day −10) until engraftment (absolute neutrophil count greater than 1 × 10 9 /l) or initiation of parenteral antibiotics due to fever and neutropenia. In children who were 12 years of age or younger, ciprofloxacin was substituted with trimethoprimsulfamethoxazole (5 mg/kg of trimethoprim) orally twice daily. The last 79 patients also received prophylactic ampicillin 250 mg orally four times daily from day +2 until engraftment or initiation of parenteral antibiotics. During aplasia, all febrile episodes (n = 164) were treated initially with ceflazidime 1 g intravenously every 8 h. Other parenteral antibiotics were added or substituted in the event of a positive blood culture. Trimethoprim-sufamethoxazale 160 mg/800 mg was administered orally twice daily every Monday and Thursday following engraftment for a total 100 to 365 days for prophylaxis against Pneumocystis carinii pneumonia. Prophylactic acyclovir 250 mg/m 2 intravenously three times daily was also administered from the initiation of myelo-ablative chemotherapy until engraftment, and was then continued orally at a dose of 400 mg twice daily until day +50 in all individuals who were sero-positive for Herpes simplex (n = 126).
Methylprednisolone, initially 0.5 mg/kg intravenously or orally, was given for 6 weeks in tapering doses, beginning at day +2. Any patient who developed three or more loose stools per day after stem cell infusion was tested for the presence of C. difficile in stool samples. Fifty microliters of stool filtrate and 0.9 ml of MRC-5 Maintenance Media (OrthoDiagnostic Systems, Raritan, NJ, USA) were incubated at 35°C for 24 to 48 h in an MRC-5 human embryonic lung (diploid) tissue culture tube (Ortho Diagnostic Systems). If a cytopathic effect was observed, the process was repeated with 100 l of stool filtrate and 100 l of 1:25 diluted C. difficile antitoxin (Virginia Tech, Blacksburg, VA, USA). An absence of cytopathic changes with the second procedure confirmed the diagnosis of C. difficile toxin.
Several transplant-related variables were examined as potential risk factors for C. difficile infection. These included age, sex, myelo-ablative chemotherapy regimen, duration of neutropenia and use of prophylactic ampicillin. Contingency table ( 2 ) analyses were used to estimate the statistical significance of each discrete variable.
Results

Incidence
Fourteen patients developed 15 instances (7.5%) of C. difficile infection at a median of 33 days (range 5 to 89 days) following stem cell infusion ( Table 2 ). The median age of these patients was 45 years (range 4 to 60 years) which was similar to the entire group of patients ( Table 1 ). The male:female ratio in infected patients was 4:10. Eleven of these individuals had an underlying solid tumor whereas the remaining patients suffered from hematologic malignancies. Underlying malignancies included breast cancer (n = 10), non-Hodgkin's lymphoma (n = 2), Ewing's sarcoma (n = 1) and neuroblastoma (n = 1). Six of 122 patients who received prophylactic ciprofloxacin within 30 days prior to myeloablative chemotherapy developed C. difficile infection compared to eight of 78 individuals who received both ciprofloxacin and ampicillin prophylactically. Moreover, three of the 14 patients who developed C. difficile infection also received intravenous antibiotics during the 30 days preceding the initiation of myeloablative chemotherapy (ceftazidime and vancomycin (n = 2) and ceftazid- ime alone (n = 1)). Five patients were neutropenic when C. difficile was isolated in stool samples.
Clinical features, treatment and outcome
Diarrhea was the most frequent presenting symptom and was observed in all infected individuals (Table 3) . Moreover, the stools were microscopically or overtly hemorrhagic in seven of these patients. Other clinical features included a temperature exceeding 38°C in nine patients and abdominal cramps in eight patients. Abdominal distention and paralytic ileus developed in two individuals. The median duration of symptoms prior to diagnosis of C. difficile infection was 5 days (range 1 to 9 days). Eleven patients received metronidazole 250-500 mg orally four times daily. Two other patients received both metronidazole and vancomycin simultaneously whereas one patient was treated only with oral vancomycin. The median duration of antibiotics therapy was 10 days (range 7-16 days). The median duration of symptoms after institution of antibiotic therapy was 5 days (range 1-10 days). One of five patients aged less than 15 years developed C. difficile infection. The clinical features in this 4-year-old male included fever, severe abdominal cramps and profuse hemorrhagic diarrhea which lasted for 1 week. Only one patient suffered a relapse of C. difficile infection 11 days after completion of treatment for the first episode. This individual was treated with a combination of metronidazole and vancomycin for the initial episode. Subsequently, metronidazole alone was utilized successfully for relapsed infection. There were no cases of treatment failure or mortality as a result of infection with C. difficile.
Risk factors
All 200 patients were included in the statistical analysis. The median number of antibiotics administered to the patients who developed C. difficile infection was four (range 2-7). Moreover, antibiotics were being administered at the time of isolation of C. difficile during 14 of these 15 episodes of infection. The median number of hospitalizations during the 2 months preceding the diagnosis of C. difficile infection was two (range 1-3). All but one of these episodes was identified during the course of a hospitalization. There was no significant difference in the number of prior hospitalizations and use of antibiotics among patients who either developed or did not develop C. difficile infection. The median interval from the date of administration of last chemotherapy until discovery of C. difficile was 36 days (range 8-92 days). Nine of the infected patients were given prophylactic acyclovir, and 14 episodes of C. difficile infection occurred while corticosteroids were being administered. None of the transplantation factors assessed statistically, such as age (P value 0.09), sex (P value 0.95), underlying malignancy (P value 0.07), type of myeloablative regimen (P value 0.15), duration of neutropenia (P value 0.48) and ampicillin (P value 0.24), proved to be of significance in predicting infection with C. difficile. Therefore, a multivariate analysis of these risk factors was not conducted.
Discussion
Clostridium difficile is isolated in 3% of normal adults. 18 However, it is recovered frequently from the hospital environment, 6, 8 especially oncology units, 7 and from stools of 13-28% of hospitalized patients.
9,10,13 Risk factors include current or recent antibiotic therapy, [3] [4] [5] administration of cancer or antiviral chemotherapy, 14, 15 prolonged hospitalization, 12 protracted neutropenia, underlying malignancy and recent surgery. 5 Pathogenic strains of C. difficile elaborate two toxins which lead to focal epithelial necrosis of the gut and even complete structural necrosis of the mucosa. 19, 20 Endoscopy demonstrates edema, friable mucosa, ulceration, submucosal nodules and pseudomembrane formation. 21 The diagnosis is confirmed by a stoolcytotoxin test which is a tissue culture assay based on cellular changes induced by toxin B in stool samples. 2, 11 However, newer enzyme immunoassays that detect toxins A and B may be equivalent in sensitivity and specificity. 4 All of our patients were diagnosed by the stool-cytotoxin test. Endoscopic evaluation can be difficult in the post-transplant period because such patients are markedly immunocompromised and may also have pancytopenia.
Only half of all hospitalized patients with C. difficile colonization develop clinical symptoms. 9, 10 Severe cases may be associated with fulminant colitis, toxic megacolon, hyperpyrexia, intestinal perforation, leukemoid reaction and death. 1, 2, 4 In fact, 3% of patients with C. difficile infection require intensive care admission and may die as a result of the severity of their illness. 22 An unusual situation is encountered in neutropenic patients where there can be a lack of diarrhea or pseudomembrane formation and individuals may develop ascites, hyperbilirubinemia and acute abdominal symptoms. 23 Treatment requires discontinuation or substitution, if possible, of the offending antibiotic followed by 10 to 14 days of vancomycin 125-500 mg orally four times daily or metronidazole 250 mg orally four times daily. 1, 4 There is no difference in the rates of response, relapse or failure between these two agents. 24, 25 Intravenous metronidazole can be utilized in patients with ileus or toxic megacolon because bactericidal concentration of the drug can be achieved in the feces even by this route of administration. 26 Relapses can be treated with oral vancomycin or metronidazole. 1, 4 The incidence of C. difficile infection and results of treatment were similar in our cohort of patients compared to other groups of hospitalized individuals. However, the incidence of fever and hemorrhagic diarrhea was higher among our patients. The presence of several previously described poor prognostic features failed to have an adverse impact on the eventual outcome of C. difficile infection in these patients. Notably, none of our patients succumbed to their infection. This is the first reported series of patients who developed infection with C. difficile after high-dose chemotherapy and autologous PBSCT. We were unable to identify any statistically significant transplant-related risk factor. Surprisingly, all of these patients recovered with standard treatment despite the presence of numerous adverse prognostic features. Clostridium difficile infection is not uncommon in this patient population and may be under-reported because diarrhea is attributed generally to other causes. We recommend that patients with diarrhea in the post-transplant setting should be evaluated for the presence of C. difficile and be treated in standard fashion once the diagnosis has been established.
